Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 497 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vascular Dysfunction Clear all
Recruiting Phase 4 Interventional

SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery

NCT05812755
View directory record Official record
Conditions
Endothelial Dysfunction, Vascular Diseases, Kidney Injury, Brain Disease, Vascular Inflammation
Interventions
Vericiguat, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 30, 2026, 6:05 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Whey Protein Effects on Gycemic Control and Vascular Function

NCT01814358
View directory record Official record
Conditions
Blood Sugar (Glucose) Control, Blood Vessel (Vascular) Dysfunction
Interventions
Whey protein powder, Control protein
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 30, 2026, 6:05 AM EDT
Active, not recruiting Not applicable Interventional

Transferring Speed of Processing Gains to Everyday Cognitive Tasks After Stroke

NCT05162781
View directory record Official record
Conditions
Stroke, Cognitive Dysfunction
Interventions
Speed of Processing Training, Instrumental Activities of Daily Living In-lab Training, Cognitive Transfer Packagke, Family Caregiver Coaching, Follow-up Phone Calls, Healthy Lifestyle In-lab Training, Healthy Lifestyle Transfer Package
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 6:05 AM EDT
Completed Not applicable Interventional

Effects of Aerobic Exercise in Patients With Pre-diabetes

NCT01860599
View directory record Official record
Conditions
Prediabetes
Interventions
Exercise, Without exercise
Behavioral
Lead sponsor
Baystate Medical Center
Other
Eligibility
20 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Oct 30, 2026, 6:05 AM EDT
Completed Early Phase 1 Interventional Results available

Pressure Assessment to Improve Outcomes After TAVR: a Registry

NCT03923530
View directory record Official record
Conditions
Hypertension, Aortic Stenosis, Calcific, Quality of Life, Heart Failure With Preserved Ejection Fraction
Interventions
Eplerenone
Drug
Lead sponsor
North Florida Foundation for Research and Education
Other
Eligibility
55 Years to 100 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 30, 2026, 6:05 AM EDT
Completed Not applicable Interventional Results available

Comparative Effects of Nebivolol and Metoprolol on Female Sexual Function

NCT00995072
View directory record Official record
Conditions
Hypertension, Female Sexual Dysfunction
Interventions
nebivolol and metoprolol succinate, metoprolol succinate and nebivolol
Drug
Lead sponsor
East Coast Institute for Research
Network
Eligibility
40 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 30, 2026, 6:05 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting

NCT01529502
View directory record Official record
Conditions
Blood Transfusion, Endothelial Physiopathology, Nitric Oxide, Pulmonary Hypertension
Interventions
Red blood Cells auto-transfusion, Inhaled Nitric Oxide (iNO) administration
Procedure · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Oct 30, 2026, 6:05 AM EDT
Completed Phase 1 Interventional

Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction

NCT00054483
View directory record Official record
Conditions
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Multiple Myeloma, Splenic Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
Interventions
bortezomib, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Oct 30, 2026, 6:05 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration

NCT01458405
View directory record Official record
Conditions
Myocardial Infarction
Interventions
CAP-1002 Allogeneic Cardiosphere-Derived Cells, Placebo
Biological · Drug
Lead sponsor
Capricor Inc.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
32
States / cities
Birmingham, Alabama • Huntsville, Alabama • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 30, 2026, 6:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders

NCT02118805
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Myasthenia Gravis, Myopathies, Stroke, Parkinson's Disease
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
20 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 30, 2026, 6:05 AM EDT
Completed Phase 4 Interventional

Characterization of LV Strain Patterns in Mildly Elevated PCWP and PAH.

NCT01800292
View directory record Official record
Conditions
Hypertension, Pulmonary Artery, Ventricular Dysfunction, Left
Interventions
sildenafil
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 30, 2026, 6:05 AM EDT
Withdrawn Phase 2 Interventional

Effects of Nitric Oxide on the Endothelium During Hemolysis.

NCT03748082
View directory record Official record
Conditions
Endothelial Dysfunction, Hemolysis Intravascular, Cardiovascular Diseases, Cardiovascular Risk Factor
Interventions
Nitric Oxide, Reactive Hyperemia Index, Endothelial Cells Collection
Drug · Diagnostic Test · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 30, 2026, 6:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.

NCT00938665
View directory record Official record
Conditions
Memory Disorders, Alzheimer Disease, Dementia, Cognitive Impairment, Frontotemporal Dementia
Interventions
COGNISION™ System
Device
Lead sponsor
Neuronetrix, Inc.
Industry
Eligibility
60 Years to 90 Years
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
7
States / cities
West Palm Beach, Florida • Lexington, Kentucky • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 30, 2026, 6:05 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Autonomic and Renal Contributions to Hypertension With ADT

NCT07848828
View directory record Official record
Conditions
Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction, Renal Disease
Interventions
Gonadotropin Releasing Hormone Agonists (GNRH), Androgen receptor (AR) inhibitor, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
40 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 30, 2026, 6:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pediatric Ventricle Function Assessment Study

NCT06739057
View directory record Official record
Conditions
RV - Right Ventricular Abnormality, LV Dysfunction, Pulmonary Hypertension, TOF
Interventions
Not listed
Lead sponsor
HBI Solutions Inc.
Industry
Eligibility
Up to 18 Years
Enrollment
3,993 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 30, 2026, 6:05 AM EDT
Completed No phase listed Observational Results available

Physiologic Effect of Topical Nitroglycerin on Microcirculation Capacity in Patients With Circulatory Shock.

NCT05102734
View directory record Official record
Conditions
Circulatory Shock, Cardiovascular Shock
Interventions
Nitroglycerin Topical Product
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Oct 30, 2026, 6:05 AM EDT
Terminated Phase 2 Interventional Results available

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

NCT03152552
View directory record Official record
Conditions
Diabetes Mellitus and Heart Failure
Interventions
LIK066, Placebo, Empagliflozin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
21
States / cities
Huntsville, Alabama • Carmichael, California • Concord, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 30, 2026, 6:05 AM EDT
Terminated Phase 4 Interventional Results available

PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

NCT00867815
View directory record Official record
Conditions
Anterior Ischemic Optic Neuropathy
Interventions
Diagnostic procedures
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
11
States / cities
Vista, California • Atlantis, Florida • Fort Myers, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 30, 2026, 6:05 AM EDT
Withdrawn Early Phase 1 Interventional

Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients

NCT00713921
View directory record Official record
Conditions
Urinary Incontinence, Bladder Dysfunction
Interventions
Fesoterodine Oral Product
Drug
Lead sponsor
Saint Thomas Health
Other
Eligibility
21 Years to 85 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 30, 2026, 6:05 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Effect of EGCG on the Body's Response to Insulin

NCT00434499
View directory record Official record
Conditions
Hypertension, Obesity, Type 2 Diabetes, Insulin Resistance
Interventions
EGCG
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 30, 2026, 6:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vascular Dysfunction During Physical Inactivity

NCT04872998
View directory record Official record
Conditions
Aging, Vascular Endothelium, Skeletal Muscle
Interventions
Step Count Reduction
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 30, 2026, 6:05 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Advancing Postmenopausal Preventive Therapy

NCT04103476
View directory record Official record
Conditions
Atherosclerosis, Cognitive Decline
Interventions
Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg, Placebo
Combination Product · Other
Lead sponsor
University of Southern California
Other
Eligibility
45 Years to 59 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 30, 2026, 6:05 AM EDT
Completed Phase 4 Interventional Results available

Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension

NCT01202175
View directory record Official record
Conditions
Pre-hypertension, Hypertension
Interventions
Nebivolol
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 30, 2026, 6:05 AM EDT
Completed Phase 2 Interventional Results available

Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI

NCT00586820
View directory record Official record
Conditions
Myocardial Reperfusion Injury
Interventions
BQ-123, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 4, 2014 · Synced Oct 30, 2026, 6:05 AM EDT